💡Join us once again as we unveil the next chapter in our “Meet Enantis” series with issue nine!💡

Our plan is to introduce all the brilliant minds that fuel Enantis’ innovation, as our company is not just about business – it’s about the people who make the magic happen!

This time, we’re thrilled to introduce Jan Vilím, our Head of Production and R&D 🧪🧬, and offer you an insightful interview that gives a glimpse into his role and experiences at Enantis. Delve into the world of production and research as Jan shares his journey, thoughts, and passions.

Meet Enantis series is a unique opportunity to get to know the people who drive Enantis’ innovation on a personal level. Stay tuned for more candid conversations that shed light on the inner workings of our company and the individuals who contribute to its success.

INTERVIEW HERE

#biotech #production #HR #randd #brnoregion

FGF2-STAB®: Clinically Proven Cosmetics Ingredient!

Enantis is thrilled to share some amazing news with you! FGF2-STAB®, a groundbreaking cosmetics ingredient, has been clinically and dermatologically tested and proven effective. It was shown that it retains skin hydration, reduces wrinkles, and softens the skin.

FGF2-STAB® underwent rigorous testing, showing impressive results. Participants experienced improved skin hydration leading to visible wrinkle reduction and softer skin. What’s more, FGF2-STAB® is safe to use, with no cytotoxicity or skin irritation observed during testing.

This verification of FGF2-STAB® as an effective cosmetics ingredient is a game-changer in achieving optimal skin health. This revolutionary product is now available for supply and licensing as an innovative cosmetics ingredient. We will be happy to hear from you if you want to give it a try in your cosmetics formulation.

Exciting times ahead!

We are happy to announce an open call for a PhD fellowship for the Marie Skłodowska-Curie European Doctoral Network BiocatCodeExpander.

Are you interested in being part of an innovative biotech team? Join Enantis and play a role in our exciting project of rational design of growth factors as therapeutically and biotechnologically attractive proteins using incorporation of non-canonical amino acids (NCAA).

More info HERE

📢 Job Opportunity: Bioinformatician Position Available 🧬🔬

We are thrilled to announce an exciting career opportunity for a talented and motivated bioinformatician to join our dynamic team! If you have a passion for bioinformatics, data analysis, and cutting-edge computational techniques, this position is perfect for you.

Join us on this exciting journey of scientific exploration and contribute to advancing our understanding of the intricate complexities of life through bioinformatics. Take the first step towards a rewarding career by applying today!

Please note that the application deadline for this position is 26^th of June 2023.

We look forward to reviewing your application and welcoming you to our team!

Bioinformatician Job advert Enantis

Our FGF2-STAB® has been given an interesting redo by a team of scientists from the University of Wroclaw. They have used our thermostable molecule to create cyclic and dimeric protein variants that might have higher potential in regenerative and cancer medicine. The resulting variants present different effects on the signaling cascade and modulate the pleiotropic effect of FGF2. Proposed applications of these new variants include wound healing – as cyclic FGF2-STAB® is more active and stable, anticancer therapy – as FGF2-STAB®-based drug carrier and also in glucose uptake – for diabetic patients that cannot be treated with insulin.

Have we aroused your interest? Read on…

https://lnkd.in/gxMM43st

Cultured meat can help us solve some of the key global problems: greenhouse gas production, excessive water usage and animal cruelty. At Enantis we are proud to contribute to a more sustainable future with our hyperstable Fibroblast Growth Factor 2 (FGF2-STAB® or FGF2-G3). This protein, originally designed for stem cell culturing, was used as a base by our scientific team to develop bovine/porcine FGF2-STAB® variants intended specifically for the cultured meat use: FGF2-STAB® MEAT!
Thanks to the positive feedback from cultured meat companies that have already tested it, we will soon make FGF2-STAB® MEAT available to everyone! Get in touch if you want some samples for testing or if you just know to know more about it.
#culturedmeat 

#sustainability

Enantis will participate at The Future of Protein Production Summit 2023 taking place online on 21 – 23 February 2023. We will be happy to meet you there. For scheduling a meeting, please contact Alzbeta Cardova, Business Development Manager of Enantis at cardova@enantis.com.

Hope to see you there!

Enantis will participate at the MEVO – Meat Evolution Leaders Summit in Berlin that takes place between 15 – 16 February 2023. Would you like to meet us there? Get in touch with Ezequiel Juritz at juritz@enantis.com and let’s schedule a meeting.

Enantis will participate at the CHPI Frankfurt that takes place between 1 – 3 November 2022. Would you like to meet us there (or online)? Get in touch with Ezequiel Juritz at juritz@enantis.com and let’s schedule a meeting.

Enantis, innovative protein engineering company, and Core Biogenesis, company focusing on ground-breaking bioproduction of proteins in plants, have recently concluded a license agreement. This license grants Core Biogenesis the rights for global use of Enantis’ patented FGF2-STAB® to be used in areas of research, cellular agriculture and cell therapy.

“We were really impressed by the scalable technology that Core Biogenesis has developed. Through this deal, our FGF2-STAB® will become available in large quantities at a competitive price and can serve the needs of cultured meat industry.” says Roman Badik, CEO of Enantis. “We strongly believe that the synergy between our companies will be beneficial for both our growing businesses”.

FGF2-STAB®, originally named FGF2-G3, was developed by Enantis and Masaryk University, using computational methods to improve thermostability of the wild-type sequence of fibroblast growth factor 2 (FGF2-WT or bFGF). While FGF2-WT quickly destabilizes in standard stem cell culture conditions, FGF2-STAB® retains full biological activity even after five days at 37°C. This allows for a more homogenous, undifferentiated stem cell culture, less frequent medium changes, and weekend-free cell culture scheduling.

“Core Biogenesis is excited to collaborate with Enantis and their innovative technology for protein design and engineering. Between Enantis’ protein engineering unique capabilities and Core Biogenesis’ ultra-scalable bioproduction platform, we strongly believe this partnership will bring major solutions for customers in the cultivated meat industry and to industrials and researchers that require large quantities of FGF-2″  said Alexandre Reeber, CEO of Core Biogenesis.

About Enantis

Enantis is a biotechnology company founded as a spin-off from Masaryk University, Czech Republic. Enantis’ expertise is based on vast experience in protein engineering and state-of-the-art software tools. Our key product, FGF2-STAB®, is a patented thermostable form of basic fibroblast growth factor that can revolutionize stem cell culturing. This protein is 50-times more stable than its native counterpart and has a fully retained biological activity. We also focus on other members of the growth factor family and are planning to bring various new thermostable growth factors on the market. More info at enantis.com.

About Core Biogenesis

Core Biogenesis developed a plant-based method to produce recombinant Growth Factors.

Their technology offer a massively-scalable bioproduction process and drastically reduce the environmental impact of manufacturing recombinant proteins. Recombinant Growth Factors are widely used and have multiple applications in ground-breaking industries. Core Biogenesis’ target markets include Cell & Gene therapy manufacturing, Cultivated meat, and Life Science R&D. Visit corebiogenesis.com

Contact email: enantis@enantis.com